Patrys Ltd
ASX:PAB

Watchlist Manager
Patrys Ltd Logo
Patrys Ltd
ASX:PAB
Watchlist
Price: 0.029 AUD -3.33% Market Closed
Market Cap: AU$9.9m

Operating Margin

-327%
Current
Declining
by 73.7%
vs 3-y average of -253.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-327%
=
Operating Income
AU$-2.7m
/
Revenue
AU$828.5k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-327%
=
Operating Income
AU$-2.7m
/
Revenue
AU$828.5k

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Patrys Ltd
ASX:PAB
9.9m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
167.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

In line with most companies in Australia
Percentile
34rd
Based on 3 951 companies
34rd percentile
-327%
Low
-14 949 200% — -526.4%
Typical Range
-526.4% — 6.1%
High
6.1% — 145 596.9%
Distribution Statistics
Australia
Min -14 949 200%
30th Percentile -526.4%
Median -25.2%
70th Percentile 6.1%
Max 145 596.9%

Patrys Ltd
Glance View

Market Cap
9.9m AUD
Industry
Biotechnology

Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. Its is also using the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The firm is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.

PAB Intrinsic Value
0.028 AUD
Overvaluation 3%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-327%
=
Operating Income
AU$-2.7m
/
Revenue
AU$828.5k
What is Patrys Ltd's current Operating Margin?

The current Operating Margin for Patrys Ltd is -327%, which is below its 3-year median of -253.3%.

How has Operating Margin changed over time?

Over the last 3 years, Patrys Ltd’s Operating Margin has decreased from -203.4% to -327%. During this period, it reached a low of -327% on Jul 30, 2025 and a high of -175.8% on Dec 31, 2022.

Back to Top